Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia

Leukemia & Lymphoma 2018

Key clinical point: Zanubrutinib, a BTK inhibitor, appears effective against Waldenström macroglobulinemia in an early study.

Major finding: Zanubrutinib had an overall response rate of 92%, and the estimated 12-month progression-free survival rate was 89%.

Study details: A phase 1 study with 73 patients evaluable for efficacy in this analysis.

Disclosures: The trial is sponsored by BeiGene. Dr. Tam reported financial relationships with BeiGene and other companies.

Read the article.


Leukemia & Lymphoma 2018